Generation of human induced pluripotent stem cell lines from healthy Korean donors (IPBi101-A, IPBi102-A, IPBi103-A, IPBi105-A, IPBi107-A, IPBi108-A, IPBi110-A, IPBi111-A, IPBi113-A, and IPBi114-A).

ISSCR standards for the use of human stem cells in basic research.

A novel HDAC6 inhibitor, CKD-504, is effective in treating preclinical models of Huntington’s disease.

Lessons learnt, and still to learn, in first in human stem cell trials.

Mitochondrial genome mutations and neuronal dysfunction of induced pluripotent stem cells derived from patients with Alzheimer's disease.

SUPT4H1-edited stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease.

Therapeutic Effect of BDNF-Overexpressing Human Neural Stem Cells (F3.BDNF) in a Contusion Model of Spinal Cord Injury in Rats

Human iPSC-derived neural precursor cells differentiate into multiple cell types to delay disease progression following transplantation into YAC128 Huntington's disease mouse model.

Intracerebral Transplants of GMP-Grade Human Umbilical Cord-Derived Mesenchymal Stromal Cells Effectively Treat Subacute-Phase Ischemic Stroke in a Rodent Model.

Neural Transplants From Human Induced Pluripotent Stem Cells Rescue the Pathology and Behavioral Defects in a Rodent Model of Huntington’s Disease.

Screening method for candidate drugs for Huntington's disease using induced pluripotent stem cells derived from Huntington's disease patients. (101535253)

Pharmaceutical composition for the treatment of stroke comprising neural precursor cells derived from human induced pluripotent stem cells. (101516352)